Erythropoietin deficiency decreases vascular stability in mice
J. Clin. Invest. Jing Chen, et al. 118:526 doi:10.1172/JCI33813 [
Go to this article.]
Figure 2Early use of Epo protects against retinopathy with reduction in vaso-obliteration and neovascularization; in contrast, late use of Epo is not protective. Retinas were whole-mounted at P17 after oxygen-induced retinopathy, showing both vaso-obliteration (VO) and neovascularization (NV). (
A) Representative retina whole-mount with PBS control (left) or early Epo injections (right) (i.p., 5,000 U/kg, P6, P8, P10, and P12). Areas of vaso-obliteration (yellow) and neovascularization (red) were quantified. Original magnification, ×5. (
B) Vaso-obliteration (***
P ≤ 0.001) and (
C) neovascularization (*
P ≤ 0.02) in the mice with early Epo treatment at P17 (PBS,
n = 40; Epo,
n = 23). (
D) Representative retina whole-mount with PBS control (left) or late Epo injections (right) (i.p., 5,000 U/kg, P14, P15, and P16) with areas of vaso-obliteration (yellow) and neovascularization (red). Original magnification, ×5. (
E) Vaso-obliteration and (
F) neovascularization in the mice with late Epo treatment (PBS,
n = 34; Epo,
n = 15).
